Maricann Group (CNSX:MARI – Get Free Report) had its target price increased by research analysts at Canaccord Genuity Group from $6.00 to $7.50 in a research note issued to investors on Monday, BayStreet.CA reports.
Separately, Raymond James raised their price target on shares of Maricann Group from $6.00 to $6.50 in a report on Tuesday, April 23rd.
Read Our Latest Research Report on MARI
Maricann Group Price Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Recommended Stories
- Five stocks we like better than Maricann Group
- Manufacturing Stocks Investing
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- Election Stocks: How Elections Affect the Stock Market
- Has This Leading Tech Stock Halted the AI Surge?
- Which Wall Street Analysts are the Most Accurate?
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
